Search | IOVS | ARVO Journals

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2023

Management of neovascular age-related macular degeneration treatment in France from 2008-2018 – the nationwide LANDSCAPE study

Catherine Creuzot Garcher; Mayer Srour; Florian Baudin; Corinne Dot; Sylvia Nghiem-Buffet; Jean-François Girmens; Cédric Collin; Anne Ponthieux; Cécile Delcourt

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2186.

ARVO Annual Meeting Abstract July 2019

HTRA1 inactivates Thrombospondin-1 mediated subretinal immune-suppression

Florian Sennlaub; Fanny Beguier; Michael Housset; Sebastien Augustin; Christophe Roubeix; Thibaud Mathis; Chiara M Eandi; Sara Touhami; Jean-Baptiste Conart; Yvrick Zagar; Mustapha Benchaboune; Jean-François Girmens; Thierry D Leveillard; Jose Alain Sahel; Przemyslaw Mike Sapieha; Xavier Guilonneau

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1723.

ARVO Annual Meeting Abstract July 2019

Healthy and pathological visual aging in a French follow-up cohort study

Karine LAGRENE; Marcia Bécu; William H Seiple; Marine Raphanel Bataille; Sonia Combariza; Michel Paques; Anne Aubois; Bertrand Duclos; Chiara Eandi; Jean-François Girmens; Saddek Mohand-Said; Angelo Arleo

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5915.

ARVO Annual Meeting Abstract June 2017

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study

Catherine P Creuzot Garcher; Pascale Massin; Laurent KODJIKIAN; Jean-Francois Girmens; Cecile DelCourt; Frank Fajnkuchen; Agnès Glacet; Pierre-Jean Guillausseau; Audrey Derveloy; Laetitia FINZI; Patrick Blin; BPE Team

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1915.

ARVO Annual Meeting Abstract June 2017

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study

Mayer Srour; Agnès Glacet; Jean-Francois Girmens; Laurent KODJIKIAN; Cecile DelCourt; Frank Fajnkuchen; Catherine P Creuzot Garcher; Pascale Massin; Pierre-Jean Guillausseau; Anne Ponthieux; Laetitia FINZI; Angela Grelaud-Boussinot; BPE Team

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4630.

ARVO Annual Meeting Abstract September 2016

Diagnosis of choroidal neovascularization in uveitis by optical coherence tomography angiography

Alexandra Pierru; Marie-Hélène Errera; Jean-Francois GIRMENS; Jonathan Benesty; Christophe Baudouin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1639.

ARVO Annual Meeting Abstract September 2016

REAL LIFE SETTING TREATMENT BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR WET AGE-RELATED MACULAR DEGENERATION: INACTIVATION OF LESION AND LONG TERM OUTCOMES

Mohamed Maher Haouas; Gilles Thuret; Philippe GAIN; Michel Paques; Jose Sahel; Jean-Francois GIRMENS

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3333.

ARVO Annual Meeting Abstract September 2016

Indocyanine green-guided targeted photocoagulation of macroaneurysms in macular edema: a pilot study

Benedicte Marie Dupas; Elise Philippakis; serge meimon; Clémence Bonnet; Jean-Francois GIRMENS; Michel Paques

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3246.

ARVO Annual Meeting Abstract September 2016

Management of diabetic macular edema with visual impairment in real-life practice in France: findings from the cross-sectional BOREAL DME study

Catherine P Garcher; Pascale G Massin; Frank Fajnkuchen; Agnes Glacet-Bernard; Laurent Kodjikian; Jean-François Maher GIRMENS; Cécile Delcourt; Pierre-Jean Guillausseau; Anne Ponthieux

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2086.

ARVO Annual Meeting Abstract June 2015

Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies

Jean-Francois GIRMENS; Franck Fajnkuchen; Eric H Souied; Joel Uzzan; Gérard Mimoun; Violaine COLASSE-MARTHELOT; Audrey Derveloy; Hassiba Oubraham; Christian Delhay; Salomon Y Cohen

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1416.

ARVO Annual Meeting Abstract June 2015

Is the arteriolar microenvironment the cause of venous nickings?

Aurelie Brolly; Jonathan Benesty; Nicolas Lerme; Edouard Koch; José-Alain Sahel; Florence Rossant; Isabelle Bloch; Jean-François Girmens; Michel Paques

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4428.

ARVO Annual Meeting Abstract April 2014

Clinical patterns of perfused central retinal vein occlusion: the initial presence of perivenular whitening shifts the balance between disc and macular edema

Michel Paques; Alexandra Pierru; Jean-François Girmens

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1079.

ARVO Annual Meeting Abstract June 2013

Acute central retinal vein occlusion followed by disc edema: a frequent cause of macular thickening without macular edema

Feng Liang; Jean François Girmens; Jose Sahel; Michel Paques

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3616.

ARVO Annual Meeting Abstract March 2012

Pattern of Retinal Ischemia during Acute Retinal Hypoperfusion

Feng Liang; José-Alain Sahel; Jean-françois Girmens; Michel Paques

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5652.

Clinical Trials May 2011

Evaluation of Retinal Function and Flicker Light-Induced Retinal Vascular Response in Normotensive Patients with Diabetes without Retinopathy

PDF

Amélie Lecleire-Collet; Isabelle Audo; Mounir Aout; Jean-François Girmens; Rénata Sofroni; Ali Erginay; Jean-François Le Gargasson; Saddek Mohand-Saïd; Taly Meas; Pierre-Jean Guillausseau; Eric Vicaut; Michel Paques; Pascale Massin
TAGS: diabetes mellitus, diabetes mellitus, type 2, electroretinography, photopsia, retinal diseases
Invest. Ophthalmol. Vis. Sci.. 2011; 52(6):2861-2867. https://doi.org/10.1167/iovs.10-5960

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Management of neovascular age-related macular degeneration treatment in France from 2008-2018 – the nationwide LANDSCAPE study

HTRA1 inactivates Thrombospondin-1 mediated subretinal immune-suppression

Healthy and pathological visual aging in a French follow-up cohort study

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study

Diagnosis of choroidal neovascularization in uveitis by optical coherence tomography angiography

REAL LIFE SETTING TREATMENT BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR WET AGE-RELATED MACULAR DEGENERATION: INACTIVATION OF LESION AND LONG TERM OUTCOMES

Indocyanine green-guided targeted photocoagulation of macroaneurysms in macular edema: a pilot study

Management of diabetic macular edema with visual impairment in real-life practice in France: findings from the cross-sectional BOREAL DME study

Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies

Is the arteriolar microenvironment the cause of venous nickings?

Clinical patterns of perfused central retinal vein occlusion: the initial presence of perivenular whitening shifts the balance between disc and macular edema

Acute central retinal vein occlusion followed by disc edema: a frequent cause of macular thickening without macular edema

Pattern of Retinal Ischemia during Acute Retinal Hypoperfusion

Evaluation of Retinal Function and Flicker Light-Induced Retinal Vascular Response in Normotensive Patients with Diabetes without Retinopathy

To View More...

You must be signed into an individual account to use this feature.